Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522651 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
A Phase 2 study of Atrial Fibrillation, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT01522651: Completed Phase 2 study of Atrial Fibrillation, sponsored by Gilead Sciences.
NCT01522651 is a Phase 2 study of Atrial Fibrillation that has completed, run by Gilead Sciences. The registered enrollment target is 134 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522651, a Phase 2 study of Atrial Fibrillation, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.
Primary Outcome
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated.
Conditions Studied
Interventions
- DRUG Ranolazine
- DRUG Dronedarone
- DRUG Ranolazine placebo
- DRUG Dronedarone placebo
Study Locations (20)
California
- Investigational Site - Beverly Hills
- Investigational Site - Newport Beach
- Investigational Site - San Francisco
Maryland
- Investigational Site - Takoma Park
- Investigational Site - Towson
Bavaria
- Investigational Site - München
- Investigational Site - Würzburg
Other
- Investigational Site - Coburg
- Investigational Site - Frankfurt
Colorado
- Investigational Site - Aurora
District of Columbia
- Investigational Site - Washington D.C.
Florida
- Investigational Site - Lakeland
New York
- Investigational Site - Utica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2012-01-24 |
| Est. Completion | 2014-03-10 |
| Phase | Phase 2 |
What the finished NCT01522651 record still lists
NCT01522651 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 4 interventions - of which Ranolazine is the first listed.
NCT01522651 names 20 study sites across 15 states, led by California, Maryland, Bavaria.
Frequently Asked Questions
What is clinical trial NCT01522651 about?
NCT01522651 is a clinical study titled "Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation". The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia...
What is the current status of trial NCT01522651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2012-01-24. Estimated completion is 2014-03-10.
What conditions does trial NCT01522651 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT01522651?
The interventions under investigation include: Ranolazine (DRUG), Dronedarone (DRUG), Ranolazine placebo (DRUG), Dronedarone placebo (DRUG).
Who is sponsoring clinical trial NCT01522651?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01522651 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01522651's enrollment target sits among peer trials
134 127th of 202 higher than 76 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
RECRUITING · Phase 2
-
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
RECRUITING · Phase 2
-
ECG Validation Study
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI